<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02504476</url>
  </required_header>
  <id_info>
    <org_study_id>20130259</org_study_id>
    <nct_id>NCT02504476</nct_id>
  </id_info>
  <brief_title>Multiple Ascending Dose Study on Safety, Tolerability, and Pharmacokinetics of AMG 581 in Healthy Subjects or Subjects With Schizophrenia or Schizoaffective</brief_title>
  <acronym>MAD</acronym>
  <official_title>A Phase I, Randomized, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMG 581 in Healthy Subjects or Subjects With Schizophrenia or Schizoaffective Disorder on Antipsychotic Medication</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out the time it takes to absorb, distribute, breakdown
      and remove the drug from the body in healthy participants and subjects with schizophrenia and
      whether it causes any side effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetic
      profile of ascending multiple oral doses of AMG 581 in healthy subjects or subjects with
      schizophrenia or schizoaffective disorder on antipsychotic medication. The study will also
      assess the effects of AMG 581 on midazolam PK in healthy subjects or subjects with
      schizophrenia or schizoaffective disorder on antipsychotic medication.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reported treatment-emergent adverse events</measure>
    <time_frame>39 days</time_frame>
    <description>Number and percent of subjects experiencing adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in systolic/diastolic blood pressure</measure>
    <time_frame>39 days</time_frame>
    <description>Summaries over time and/or changes from baseline over time in systolic and/or diastolic blood pressure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in heart rate</measure>
    <time_frame>39 days</time_frame>
    <description>Summaries over time and/or changes from baseline over time in heart rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in respiratory rate</measure>
    <time_frame>39 days</time_frame>
    <description>Summaries over time and/or changes from baseline over time in respiratory rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in temperature</measure>
    <time_frame>39 days</time_frame>
    <description>Summaries over time and/or changes from baseline over time in temperature</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in ECGs</measure>
    <time_frame>39 days</time_frame>
    <description>Summaries over time and/or changes from baseline over time in ECGs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum change from baseline in QTc in ECGs and number and percentage of subjects with maximum changes exceeding prespecified limits in each group</measure>
    <time_frame>39 days</time_frame>
    <description>Subjects' maximum change from baseline in QTc and the number and percentage of subjects in each group</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum post-baseline QTc values and number and percentage of subjects with maximum post-baseline QTc values exceeding prespecified limits in each group</measure>
    <time_frame>39 days</time_frame>
    <description>Subjects' maximum post-baseline values and the number and percentage of subjects in each group</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Scores at each study visit for Simpson Angus Scale (SAS)</measure>
    <time_frame>39 days</time_frame>
    <description>Summaries over time and/or changes from baseline over time in changes in Simpson Angus Scale (SAS) score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Scores at each study visit for Barnes Akathisia Rating Scale (BARS)</measure>
    <time_frame>39 days</time_frame>
    <description>Summaries over time and/or changes from baseline over time in in Barnes Akathisia Rating Scale (BARS) score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subject incidence of treatment-emergent suicidal ideation and behavior as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)</measure>
    <time_frame>39 days</time_frame>
    <description>Subject incidence of treatment-emergent suicidal ideation and behavior as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS) summarized by cohort</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare PK parameter (Cmax) between Day 1 and Day 18</measure>
    <time_frame>18 days</time_frame>
    <description>Compare PK parameter (Cmax) between Day 1 and Day 18</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare PK parameter (AUC) between Day 1 and Day 18</measure>
    <time_frame>18 days</time_frame>
    <description>Compare PK parameter (AUC) between Day 1 and Day 18</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare PK parameter (tmax) Compare PK parameter (tmax) between Day 1 and Day 18</measure>
    <time_frame>18 days</time_frame>
    <description>Compare PK parameter (tmax) Compare PK parameter (tmax) between Day 1 and Day 18</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK parameters of midazolam and 1-OH midazolam</measure>
    <time_frame>36 days</time_frame>
    <description>Cmax and AUC prior to versus following AMG 581 administration</description>
  </secondary_outcome>
  <other_outcome>
    <measure>AMG 581 metabolites in plasma</measure>
    <time_frame>39 days</time_frame>
    <description>Metabolites of AMG 581 in plasma</description>
  </other_outcome>
  <other_outcome>
    <measure>Cmax and AUC of AMG 581 prior to versus following midazolam administration</measure>
    <time_frame>36 days</time_frame>
    <description>Cmax and AUC prior to versus following AMG 581 administration</description>
  </other_outcome>
  <other_outcome>
    <measure>Subjective experience following administration of AMG 581</measure>
    <time_frame>39 days</time_frame>
    <description>Subjective experience of study subjects following administration of AMG 581 as measured by the Bond and Lader visual analogue scales (VAS)</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in psychotic symptoms following administration of AMG 581</measure>
    <time_frame>39 days</time_frame>
    <description>Subjective experience of study subjects following administration of AMG 581 as measured by the Positive and Negative Syndrome Scale (PANSS) (subjects with schizophrenia or schizoaffective disorder receiving antipsychotic treatment only)</description>
  </other_outcome>
  <other_outcome>
    <measure>Relationship between QTc and temperature</measure>
    <time_frame>39 days</time_frame>
    <description>To explore the relationship between changes in QTc and changes in body temperature</description>
  </other_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Schizophrenia or Schizoaffective Disorder</condition>
  <arm_group>
    <arm_group_label>AMG 581 - Dose 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AMG 581 - Dose 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AMG 581 - Dose 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AMG 581 - Dose 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - Dose 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - Dose 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - Dose 3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - Dose 4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AMG 581/Midazolam - Drug Interaction</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 581</intervention_name>
    <description>Active drug</description>
    <arm_group_label>AMG 581 - Dose 1</arm_group_label>
    <arm_group_label>AMG 581 - Dose 2</arm_group_label>
    <arm_group_label>AMG 581 - Dose 3</arm_group_label>
    <arm_group_label>AMG 581 - Dose 4</arm_group_label>
    <arm_group_label>Placebo - Dose 1</arm_group_label>
    <arm_group_label>AMG 581/Midazolam - Drug Interaction</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo - Dose 1</arm_group_label>
    <arm_group_label>Placebo - Dose 2</arm_group_label>
    <arm_group_label>Placebo - Dose 3</arm_group_label>
    <arm_group_label>Placebo - Dose 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>Interaction</description>
    <arm_group_label>AMG 581/Midazolam - Drug Interaction</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Provided informed consent prior to initiation of any study-specific
        activities/procedures; -male or female subjects should be between the ages of 18 and 45
        years (18-55 years for subjects with schizophrenia);-non-nicotine or non-tobacco (healthy
        subjects only); - no history of relevant medical disorders; - BMI ≥ 18.0; - females of
        non-reproductive potential; - males practicing effective birth control; - avoid
        tanning/direct sunlight; - schizophrenia or schizoaffective disorder; PANSS score ≤ 4
        points on following items (i.e. conceptual disorganization, hallucinatory behavior,
        excitement, suspiciousness/persecution, hostility, depression, anxiety, disorientation,
        uncooperativeness, disturbance of volition, and poor impulse control) / total score ≤ 80
        points

        Exclusion Criteria:

          -  females lactating/breastfeeding; pregnant partners of male subjects; essential tremor
             or gait disturbance; - history of hereditary shorten QT syndrome; - malignancy or
             tumor (other than skin cancers); - history of GI disease that could interfere with
             absorption; - QTc ≥ 450 msec or ≤ 380 msec; - HbA1c ≥ 7%;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parexel</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2015</study_first_submitted>
  <study_first_submitted_qc>July 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2015</study_first_posted>
  <last_update_submitted>March 4, 2016</last_update_submitted>
  <last_update_submitted_qc>March 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Schizophrenia or Schizoaffective Disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

